Mahmoud A. Elrehany
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mahmoud A. Elrehany has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Usama Ramadan Abdelmohsen
Department of Pharmacognosy, Faculty of Pharmacy, Deraya University, Minia, Egypt
3 shared publications - Abeer H. Elmaidomy
Department of Pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt
1 shared publication - Ahmed E. Allam
Department of Pharmacognosy, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt
1 shared publication - Ahmed M. Sayed
Department of Pharmacognosy, Faculty of Pharmacy Nahda University Beni‐Suef Egypt
1 shared publication Ahmed S. Abdel-Samea
1 shared publication- Alaa M. Hayallah
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sphinx University, New Assiut, Egypt
1 shared publication
Latest Publications
- 28 July 2026
- Published by Elsevier in South African Journal of Botany
- Vol. 196, 937-950
M. alba Leaves attenuate nitroglycerin-induced migraine via coordinated modulation of the CGRP/COX-2/TRP axis: A metabolomic and in silico study
- 28 July 2026
- Published by Elsevier in South African Journal of Botany
- Vol. 196, 937-950
M. alba Leaves attenuate nitroglycerin-induced migraine via coordinated modulation of the CGRP/COX-2/TRP axis: A metabolomic and in silico study
- Open Access
- 11 July 2025
- Published by Gdanski Uniwersytet Medyczny in European Journal of Translational and Clinical Medicine
- Vol. 8 (1) , 19-31
Role of zinc and vitamin D in modulating diabetic nephropathy in an experimental model
Role of zinc and vitamin D in modulating diabetic nephropathy in experimental models. Background: Diabetes mellitus (DM) manifests itself in consistently high blood glucose concentrations as a result of insufficient insulin secretion...
- 11 July 2025
- Published by Gdanski Uniwersytet Medyczny in European Journal of Translational and Clinical Medicine
- Vol. 8 (1) , 19-31
Open AccessRole of zinc and vitamin D in modulating diabetic nephropathy in an experimental model
Role of zinc and vitamin D in modulating diabetic nephropathy in experimental models. Background: Diabetes mellitus (DM) manifests itself in consistently high blood glucose concentrations as a result of insufficient insulin secretion...
- 23 March 2025
- Published by Wiley in Chemistry & Biodiversity
- Vol. 22 (7) , e202402110
Olea europaea L. cv. Nepal Leaf Extract Alleviates Dyslipidemia and Inflammation Related to Obesity in Rabbits: A Network Pharmacology Approach Revealing Effective Antihyperlipidemic Bioactive Compounds
The current study investigated the effects of Olea europaea L. cv. Nepal (OEN) leaf extract on obesity‐related disorders in rabbits. OEN extract, in dose 100 mg/kg body weight, significantly reduced cholesterol (TC), triglycerides (TAG), and inflammatory markers (MCP‐1, VCAM‐1, IL‐6, IL‐1β, TNFα, NF‐κB) in both preventative and treatment groups. In addition, heart tissue displayed near‐normal collagen fiber distribution. LC‐HRESIMS analysis tentatively identified 20 metabolites (1–20) in OEN, including lignans, secoiridoids, and triterpenoids. Network pharmacology analysis suggested 8‐hydroxy‐p‐menth‐1‐en‐7‐oic‐acid (13), 6,7‐dihydroxy‐2H‐1‐benzopyran‐2‐one 6‐O‐d‐glucopyranoside (5), and 3‐hydroxy‐12‐oleanen‐28‐oic‐acid (20) as key antihyperlipidemic compounds, potentially targeting pathways involved in hyperlipidemia regulation. Furthermore, in silico studies revealed that lignans (compounds 1, 2, and 16) from OEN may bind and inhibit HMG‐CoA reductase, a crucial enzyme in cholesterol metabolism. These results indicate the potential of using OEN leaf extract as a therapeutic strategy for managing hyperlipidemia and inflammation associated with obesity. More investigation is necessary to confirm and validate these results and explore the extract's full therapeutic potential.
- 23 March 2025
- Published by Wiley in Chemistry & Biodiversity
- Vol. 22 (7) , e202402110
Olea europaea L. cv. Nepal Leaf Extract Alleviates Dyslipidemia and Inflammation Related to Obesity in Rabbits: A Network Pharmacology Approach Revealing Effective Antihyperlipidemic Bioactive Compounds
The current study investigated the effects of Olea europaea L. cv. Nepal (OEN) leaf extract on obesity‐related disorders in rabbits. OEN extract, in dose 100 mg/kg body weight, significantly reduced cholesterol (TC), triglycerides (TAG), and inflammatory markers (MCP‐1, VCAM‐1, IL‐6, IL‐1β, TNFα, NF‐κB) in both preventative and treatment groups. In addition, heart tissue displayed near‐normal collagen fiber distribution. LC‐HRESIMS analysis tentatively identified 20 metabolites (1–20) in OEN, including lignans, secoiridoids, and triterpenoids. Network pharmacology analysis suggested 8‐hydroxy‐p‐menth‐1‐en‐7‐oic‐acid (13), 6,7‐dihydroxy‐2H‐1‐benzopyran‐2‐one 6‐O‐d‐glucopyranoside (5), and 3‐hydroxy‐12‐oleanen‐28‐oic‐acid (20) as key antihyperlipidemic compounds, potentially targeting pathways involved in hyperlipidemia regulation. Furthermore, in silico studies revealed that lignans (compounds 1, 2, and 16) from OEN may bind and inhibit HMG‐CoA reductase, a crucial enzyme in cholesterol metabolism. These results indicate the potential of using OEN leaf extract as a therapeutic strategy for managing hyperlipidemia and inflammation associated with obesity. More investigation is necessary to confirm and validate these results and explore the extract's full therapeutic potential.
- Open Access
- 7 October 2020
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 10 (60) , 36920-36929
Isolation and characterization of novel acetylcholinesterase inhibitors from Ficus benghalensis L. leaves
Metabolic profiling of the crude methanolic extract of Ficus benghalensis leaves has revealed the presence of different phenolic and nitrogenous compounds including cerebrosides and tetrapyrrole pigments. A phytochemical study of the ethyl acetate fraction resulted in the identification of three known compounds, namely carpachromene (1), alpha amyrine acetate (2), and mucusoside (3) together with one new fatty acid glycoside, named 2-O-α-L-rhamnopyranosyl-hexacosanoate-β-D-glucopyranosyl ester (4). The compounds were identified using 1D, 2D NMR, and HR-ESIMS techniques as well as via comparison to other literature. Studies on the acetylcholinesterase inhibition potential and antioxidant activity were carried out on the total methanolic leaf extract, ethyl acetate fraction, and the isolated compounds. The results revealed the potent acetylcholinesterase inhibition of mucusoside alongside a new compound. Docking studies were also performed to confirm the possible interaction between the isolated compounds and acetylcholinesterase accompanying Alzheimer's disease progress.
- 7 October 2020
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 10 (60) , 36920-36929
Open AccessIsolation and characterization of novel acetylcholinesterase inhibitors from Ficus benghalensis L. leaves
Metabolic profiling of the crude methanolic extract of Ficus benghalensis leaves has revealed the presence of different phenolic and nitrogenous compounds including cerebrosides and tetrapyrrole pigments. A phytochemical study of the ethyl acetate fraction resulted in the identification of three known compounds, namely carpachromene (1), alpha amyrine acetate (2), and mucusoside (3) together with one new fatty acid glycoside, named 2-O-α-L-rhamnopyranosyl-hexacosanoate-β-D-glucopyranosyl ester (4). The compounds were identified using 1D, 2D NMR, and HR-ESIMS techniques as well as via comparison to other literature. Studies on the acetylcholinesterase inhibition potential and antioxidant activity were carried out on the total methanolic leaf extract, ethyl acetate fraction, and the isolated compounds. The results revealed the potent acetylcholinesterase inhibition of mucusoside alongside a new compound. Docking studies were also performed to confirm the possible interaction between the isolated compounds and acetylcholinesterase accompanying Alzheimer's disease progress.